Forbius:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Forbius - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11245
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Forbius is a clinical stage pharmaceutical company that designs and develops biotherapeutics with selective anti-tumor properties for the treatment of cancer and fibrotic diseases. The company’s pipeline product portfolio includes AVID100, anti-EGFR antibody-drug conjugate for treating solid tumors; AVID200, Isoform-selective TGF- beta inhibitor neutralizing promotion of cancer metastasis, negative effects on hematopoiesis and cardiac toxicity; AVID300 targeting fibrosis and subcutaneous formulation; and AVID400. Its ADCs prevents the inadvertent destruction of normal tissues, unlike traditional chemotherapies, which leads to safe and effective anti-cancer treatment. The company also offers preclinical and early-stage clinical development of its proprietary compounds. Forbius is headquartered in Austin, Texas, the US.

Forbius – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forbius, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forbius, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forbius, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Forbius, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Formation Biologics Raises Funds through Series B Venture Financing 10
Formation Biologics to Raise USD1 Million in Venture Financing 11
AvidBiologics Raises Funds through Venture Financing 12
Formation Biologics Raises Funds through Seed Financing 13
Partnerships 14
AvidBiologics Enters Into Co-Development Agreement With National Research Council of Canada 14
Forbius – Key Competitors 15
Forbius – Key Employees 16
Forbius – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Corporate Communications 18
May 15, 2017: Formation Biologics Announces Appointment of Dr. Anthony Tolcher to its Board of Directors 18
Product News 19
05/15/2017: Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Forbius, Pharmaceuticals & Healthcare, Key Facts 2
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forbius, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forbius, Deals By Therapy Area, 2012 to YTD 2018 8
Forbius, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Formation Biologics Raises Funds through Series B Venture Financing 10
Formation Biologics to Raise USD1 Million in Venture Financing 11
AvidBiologics Raises Funds through Venture Financing 12
Formation Biologics Raises Funds through Seed Financing 13
AvidBiologics Enters Into Co-Development Agreement With National Research Council of Canada 14
Forbius, Key Competitors 15
Forbius, Key Employees 16
Forbius, Other Locations 17

List of Figures
Forbius, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Forbius, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forbius, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Forbius, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forbius, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Forbius:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National Cancer Centre Singapore:製薬・医療:M&Aディール及び事業提携情報
    Summary National Cancer Centre Singapore (NCCS) is a cancer research centre that offers research, education, clinical services, and patient care services. The centre offers services such as medical oncology, oncologic imaging, palliative medicine, pharmacy, psychosocial oncology, public education, r …
  • Forbius:製薬・医療:M&Aディール及び事業提携情報
    Summary Forbius is a clinical stage pharmaceutical company that designs and develops biotherapeutics with selective anti-tumor properties for the treatment of cancer and fibrotic diseases. The company’s pipeline product portfolio includes AVID100, anti-EGFR antibody-drug conjugate for treating solid …
  • Heerema International Group Services SA:企業の戦略的SWOT分析
    Heerema International Group Services SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Endress+Hauser AG:企業の戦略的SWOT分析
    Endress+Hauser AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Wns (Holdings) Limited:企業の戦略・SWOT・財務分析
    Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Australian Mines Limited:企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Four Seasons Hotels and Resorts:企業の戦略的SWOT分析
    Four Seasons Hotels and Resorts - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Alzinova AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Alzinova AB (Alzinova) is a pharmaceutical company that discovers and develops therapeutics for the treatment of Alzheimer’s disease. The company develops amyloid beta CC peptide technology, which offers long-term research and development capabilities including the discovery and development …
  • Gainesville Regional Utilities:企業の戦略的SWOT分析
    Gainesville Regional Utilities - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Zahroof Valves Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Zahroof Valves Inc (Zahroof Valves) is a manufacturer and supplier of industrial valves. The company offers straightflo valve (SF) for use in reciprocating gas compressors. Its valves are used in gas production, gas gathering, gas transmission, gas storage and gas distribution applications. …
  • Empyrean Energy PLC (EME):企業の財務・戦略的SWOT分析
    Summary Empyrean Energy PLC (Empyrean Energy) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company's projects include China Block 29/11 project, Duyung PSC project, and Sacramento Basin Projects. Its Duyung PSC project covers a …
  • SOGAZ Insurance Group:企業の戦略・SWOT・財務分析
    SOGAZ Insurance Group - Strategy, SWOT and Corporate Finance Report Summary SOGAZ Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Termas De Puyehue S.A.:企業の戦略・SWOT・財務分析
    Termas De Puyehue S.A. - Strategy, SWOT and Corporate Finance Report Summary Termas De Puyehue S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Guided Therapeutics Inc (GTHP):企業の財務・戦略的SWOT分析
    Summary Guided Therapeutics Inc (GTI), formerly SpectRx Inc is a biotechnology company that offers platform technology for the early detection of disease that leads to cancer. The company provides products for the non-invasive cervical cancer detection markets. Its products include luviva, a non-inv …
  • Vienna Insurance Group AG:企業の戦略・SWOT・財務情報
    Vienna Insurance Group AG - Strategy, SWOT and Corporate Finance Report Summary Vienna Insurance Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • General Electric Capital Corporation:戦略・SWOT・企業財務分析
    General Electric Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary General Electric Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Revolution Medicines Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Revolution Medicines Inc (Revolution Medicines) is a drug development company that discovers and develops new medicines and therapies for cancer patients. The company’s programs include SHP2 Program, 4EBP1 Program and mTORC1 Program. It develops REVBLOCKS platform, an integrated suite of mod …
  • Siemens Gamesa Renewable Energy S.A.:企業の戦略・SWOT・財務情報
    Siemens Gamesa Renewable Energy S.A. - Strategy, SWOT and Corporate Finance Report Summary Siemens Gamesa Renewable Energy S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Xerium Technologies Inc:企業の戦略的SWOT分析
    Xerium Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Proteus Digital Health Inc:企業の戦略的SWOT分析
    Proteus Digital Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆